Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers

NCT ID NCT07129252

Disease control Sponsor: Crinetics Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests a new drug called CRN09682 in people with progressive metastatic neuroendocrine neoplasms and other solid tumors that have a specific marker (SST2). The trial has two phases: first, finding the safest dose, then testing that dose in more patients. About 150 participants will be enrolled to see if the drug is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CRN09682 (a drug given intravenously that targets somatostatin receptor type 2 on tumor cells)
What this could lead to
If successful, this could lead to a new treatment option for people with certain neuroendocrine and other solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 150 participants, so the drug may not prove effective or safe in larger groups. Side effects, including severe ones, are possible and being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression. * Have one or more measurable disease location per RECIST version 1.1. * Have a tumor that expresses SSR confirmed by SSR imaging. * Have an ECOG performance status of 0, 1, or 2. Exclusion Criteria: * Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT. * Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors. * Use of anticancer agents within specified intervals prior to the first dose of study drug. * Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug. * Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug. * Participants with carcinoid syndrome. * Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer. * Have prior treatment with MMAE. * Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and/or MMAE.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis neuroendocrine carcinoma neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine neoplasm Neuroendocrine tumors SST2-positive neuroendocrine neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    27 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Crinetics Study Site

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Crinetics Study Site

    RECRUITING

    Duarte, California, 91010, United States

  • Crinetics Study Site

    RECRUITING

    Newport Beach, California, 92663, United States

  • Crinetics Study Site

    RECRUITING

    Orange, California, 92868, United States

  • Crinetics Study Site

    RECRUITING

    San Francisco, California, 60637, United States

  • Crinetics Study Site

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Crinetics Study Site

    RECRUITING

    Denver, Colorado, 80218, United States

  • Crinetics Study Site

    RECRUITING

    New Haven, Connecticut, 48201, United States

  • Crinetics Study Site

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Crinetics Study Site

    RECRUITING

    Lexington, Kentucky, 40536, United States

  • Crinetics Study Site

    RECRUITING

    Metairie, Louisiana, 70006, United States

  • Crinetics Study Site

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Crinetics Study Site

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • Crinetics Study Site

    RECRUITING

    Rochester, Minnesota, 53905, United States

  • Crinetics Study Site

    RECRUITING

    New York, New York, 10016, United States

  • Crinetics Study Site

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Crinetics Study Site

    RECRUITING

    Philadelphia, Pennsylvania, 19111, United States

  • Crinetics Study Site

    RECRUITING

    Austin, Texas, 78758, United States

  • Crinetics Study Site

    RECRUITING

    Houston, Texas, 70030, United States

  • Crinetics Study Site

    RECRUITING

    Irving, Texas, 75039, United States

  • Crinetics Study Site

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Crinetics Study Site

    RECRUITING

    Charlottesville, Virginia, 22908, United States

  • Crinetics Study Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Crinetics Study Site

    RECRUITING

    Barcelona, 08023, Spain

  • Crinetics Study Site

    RECRUITING

    Barcelona, 08035, Spain

  • Crinetics Study Site

    RECRUITING

    Madrid, 28040, Spain

  • Crinetics Study Site

    RECRUITING

    Madrid, 28041, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.